Caroline M. Robb
Affiliations: | 2013-2017 | University of Nebraska Medical Center, Omaha, NE, United States |
Google:
"Caroline Robb"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Amarnath (Amar) Natarajan | grad student | 2013-2017 | University of Nebraska Medical Center |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Robb CM, Kour S, Contreras JI, et al. (2020) Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 11: 2462-2463 |
| Rana S, Kour S, Sonawane YA, et al. (2020) Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK. Chemical Biology & Drug Design |
| Kour S, Rana S, Contreras JI, et al. (2019) CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429 |
| Contreras JI, Robb CM, King HM, et al. (2018) Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. Acs Chemical Biology |
| Robb CM, Kour S, Contreras JI, et al. (2018) Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 9: 5216-5232 |
| Robb CM, Contreras JI, Kour S, et al. (2017) Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chemical Communications (Cambridge, England) |
| Agarwal E, Robb CM, Smith LM, et al. (2017) Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis. Oncogene |
| Robb CM. (2015) Abstract 3088: Inhibition of CDK5 in colorectal cancer Cancer Research. 75: 3088-3088 |